1477 — Ocumension Therapeutics Share News
0.000.00%
Last trade - 00:00- HK$3.71bn
- HK$3.43bn
- CNY804.35m
Brief: Ocumension Therapeutics Says Dexamethasone Intraocular Suspension Application Accepted By NMPA
Brief: Ocumension Therapeutics Says HY Adjusted Net Loss Rmb57.5 Million
China's Ocumension Therapeutics H1 revenue surges on higher ophthalmic product sales
Ocumension jumps most in three months on China nod for new drug application
Brief: Ocumension Therapeutics Says NMPA Approves Ot-502 (Dexycu) New Drug Application In China
Brief: Ocumension Therapeutics Says Tim Ruan Resigns As CFO
Brief: Ocumension Therapeutics Says OT-702 Approved For Marketing By NMPA In China
Brief: Ocumension Therapeutics Says Clinical Trial Authorization For Initiating A Phase III Clinical Trial Of OT-802 Accepted In China
Brief: Ocumension Therapeutics Sees Revenue RMB408 To RMB420 Million For Year
Brief: Ocumension Therapeutics Says New Drug Application Of OT-502 Accepted By NMPA China
Brief: Ocumension Therapeutics Says Co To Repurchase Shares Using Up To Aggregate HK$200 Million
Brief: Ocumension Therapeutics Says Group And Alcon Enter Transaction
Brief: Ocumension Therapeutics Posts HY Loss RMB151.3 Million
Brief: Ocumension Therapeutics H1 Revenue RMB167.6 Million
Brief: Ocumension Therapeutics Says Biologic License Application For Ot-702 Accepted By National Medical Products Administration
Brief: Ocumension Therapeutics Says Revenue Increased 55.0% For Year To RMB246.4 Mln
Brief: Ocumension Therapeutics Announces Disposal Of Shares In Eyepoint Pharmaceuticals
Brief: Ocumension Therapeutics Says Approval Received For Marketing Ot-703 In Hong Kong
China's Ocumension Therapeutics jumps on share buy-back plan